NEW YORK (GenomeWeb News) – Zygem and Phthisis Diagnostics announced Thursday that they will collaborate on developing products for the detection of infectious pathogens in complex samples, such as stool, blood, and water.

The partnership will combine Zygem's enzymatic nucleic acid extraction technology with Phthisis' molecular diagnostic test expertise to develop products that can rapidly obtain high-quality DNA from infectious pathogens. The firms will initially focus on extracting pathogen DNA from stool.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.